New Products Could Add Over $70 Billion to the Pharmaceutical Market in Five Years
While this report looks at the entire Phama R&D pipeline to 2015, a key focus is the increasing role of biopharmaceutical products. The growing interest in biotechnology development has transitioned the pharmaceutical industry to biopharmaceuticals in less than a decade.
Rockville, MD, June 19, 2010 --(PR.com)-- MarketResearch.com has announced the addition of Kalorama Information’s new report “World Pharmaceutical and Biopharmaceutical Market, 2010-2015 (Pipeline Analysis of the Top 50 Companies)” to their collection of reports. For more information, visit:
http://www.marketresearch.com/product/display.asp?productid=2691449
The pharmaceutical market may soon see the result of an increase in research and development at Big Pharma over the past few years, according to healthcare market research publisher Kalorama Information. The top fifty pharmaceutical companies in the world have some 550 projects in late stage development, and Kalorama Information estimates that these projects have the potential to add a value of more than $70 billion in additional revenues to the pharmaceutical market by 2015.
According to the report, drugs in the oncology segment are expected to make a significant impact on current markets, increasing competition and providing advanced alternatives to current therapies. There are over 140 cancer drugs in development and these alone could possibly make up nearly a third of the potential value that will be added to the pharmaceutical market. This is followed by development projects in the areas of cardiovascular and blood, neurotherapeutics, respiratory and inflammation, infectious diseases, gastrointestinal drugs, and other drugs.
Biopharmaceutical projects dominate these late-stage efforts, and should provide the bulk of the growth in revenue. The report indicates that traditional pharmaceutical companies such as Pfizer, Merck and Novartis have joined the biopharmaceutical industry lead by Amgen and Gilead Sciences, and their pipelines include a number of monoclonal antibody products for diseases such as renal, gastric and breast cancer. The line between what is a pharmaceutical company and what is a biopharmaceutical company is becoming blurred, according to the report. Many large firms told Kalorama Information they consider themselves both pharmaceutical and biopharmaceutical companies.
These and many more topics, as well as a complete review of the late-stage projects of 50 companies, are presented in “World Pharmaceutical and Biopharmaceutical Market, 2010-2015 (Pipeline Analysis of the Top 50 Companies).” For more information, visit:
http://www.marketresearch.com/product/display.asp?productid=2691449
Contact:
Veronica Franco
MarketResearch.com
vfranco@marketresearch.com
240.747.3016
###
http://www.marketresearch.com/product/display.asp?productid=2691449
The pharmaceutical market may soon see the result of an increase in research and development at Big Pharma over the past few years, according to healthcare market research publisher Kalorama Information. The top fifty pharmaceutical companies in the world have some 550 projects in late stage development, and Kalorama Information estimates that these projects have the potential to add a value of more than $70 billion in additional revenues to the pharmaceutical market by 2015.
According to the report, drugs in the oncology segment are expected to make a significant impact on current markets, increasing competition and providing advanced alternatives to current therapies. There are over 140 cancer drugs in development and these alone could possibly make up nearly a third of the potential value that will be added to the pharmaceutical market. This is followed by development projects in the areas of cardiovascular and blood, neurotherapeutics, respiratory and inflammation, infectious diseases, gastrointestinal drugs, and other drugs.
Biopharmaceutical projects dominate these late-stage efforts, and should provide the bulk of the growth in revenue. The report indicates that traditional pharmaceutical companies such as Pfizer, Merck and Novartis have joined the biopharmaceutical industry lead by Amgen and Gilead Sciences, and their pipelines include a number of monoclonal antibody products for diseases such as renal, gastric and breast cancer. The line between what is a pharmaceutical company and what is a biopharmaceutical company is becoming blurred, according to the report. Many large firms told Kalorama Information they consider themselves both pharmaceutical and biopharmaceutical companies.
These and many more topics, as well as a complete review of the late-stage projects of 50 companies, are presented in “World Pharmaceutical and Biopharmaceutical Market, 2010-2015 (Pipeline Analysis of the Top 50 Companies).” For more information, visit:
http://www.marketresearch.com/product/display.asp?productid=2691449
Contact:
Veronica Franco
MarketResearch.com
vfranco@marketresearch.com
240.747.3016
###
Contact
MarketResearch.com
Veronica Franco
240.747.3016
www.marketresearch.com/
Veronica Franco
240.747.3016
www.marketresearch.com/
Contact
Categories